HDAC9 and anemia: Similar to the results of DNMT inhibitors (e.g., 5-aza-dC) in clinical trials [50], HDAC paninhibitors approved by the Food and Drug Administration (FDA) might lead to side effects, including cardiac disturbance (arrhythmias), gastric issues (vomiting), or hematologic imbalance (anemia) [48].